Preclinical research corroborates these results, showing that anti‐CD19 CAR‐T cells can mitigate EAE, a commonly used animal model of MS, by depleting B cells in both peripheral tissues and the CNS [78]. This evidence concerns the gene CD19 and myeloid sarcoma.